9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction

A phase II trial of the University of Chicago phase II consortium

Hedy L. Kindler, Anjali Avadhani, Kurombi Wade-Oliver, Theodore Karrison, Sridhar Mani, Everett E. Vokes

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

9-Aminocamptothecin (9-AC) is a water-insoluble camptothecin derivative that demonstrated broad activity in pre-clinical studies. In vitro, greater anti-tumor efficacy can be achieved with prolonged administration. A minor response was observed in gastric cancer in a phase I study. We conducted a phase II study of 9-AC in 15 patients with previously untreated metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction. 9-AC was administered at a dose of 25 μg/m2/h over 120 hours (3000 μg/m2 over 5 days) on two consecutive weeks every 21 days. Fourteen patients were evaluable for response. There were no objective responses. Three patients had stable disease lasting a median of 3.4 months (range 1.6-4.3 months). Median time to progression was 1.4 months; median survival was 5.2 months. Grade 3 neutropenia developed in 20% of patients, and anemia in 7%. Grade 3 nausea and fatigue each developed in 7% of patients. We conclude that 9-AC given by 120-hour continuous infusion demonstrates no clinical activity in patients with metastatic gastric cancer.

Original languageEnglish (US)
Pages (from-to)323-327
Number of pages5
JournalInvestigational New Drugs
Volume22
Issue number3
DOIs
StatePublished - Aug 2004

Fingerprint

9-aminocamptothecin
Esophagogastric Junction
Stomach
Adenocarcinoma
Stomach Neoplasms
Camptothecin
Neutropenia
Nausea
Fatigue
Anemia

Keywords

  • 9-aminocamptothecin
  • Clinical trial
  • Gastric cancer
  • Gastroesophageal junction

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction : A phase II trial of the University of Chicago phase II consortium. / Kindler, Hedy L.; Avadhani, Anjali; Wade-Oliver, Kurombi; Karrison, Theodore; Mani, Sridhar; Vokes, Everett E.

In: Investigational New Drugs, Vol. 22, No. 3, 08.2004, p. 323-327.

Research output: Contribution to journalArticle

@article{eccb80f60c454d72b5478f90348e59ff,
title = "9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium",
abstract = "9-Aminocamptothecin (9-AC) is a water-insoluble camptothecin derivative that demonstrated broad activity in pre-clinical studies. In vitro, greater anti-tumor efficacy can be achieved with prolonged administration. A minor response was observed in gastric cancer in a phase I study. We conducted a phase II study of 9-AC in 15 patients with previously untreated metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction. 9-AC was administered at a dose of 25 μg/m2/h over 120 hours (3000 μg/m2 over 5 days) on two consecutive weeks every 21 days. Fourteen patients were evaluable for response. There were no objective responses. Three patients had stable disease lasting a median of 3.4 months (range 1.6-4.3 months). Median time to progression was 1.4 months; median survival was 5.2 months. Grade 3 neutropenia developed in 20{\%} of patients, and anemia in 7{\%}. Grade 3 nausea and fatigue each developed in 7{\%} of patients. We conclude that 9-AC given by 120-hour continuous infusion demonstrates no clinical activity in patients with metastatic gastric cancer.",
keywords = "9-aminocamptothecin, Clinical trial, Gastric cancer, Gastroesophageal junction",
author = "Kindler, {Hedy L.} and Anjali Avadhani and Kurombi Wade-Oliver and Theodore Karrison and Sridhar Mani and Vokes, {Everett E.}",
year = "2004",
month = "8",
doi = "10.1023/B:DRUG.0000026259.28395.c2",
language = "English (US)",
volume = "22",
pages = "323--327",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction

T2 - A phase II trial of the University of Chicago phase II consortium

AU - Kindler, Hedy L.

AU - Avadhani, Anjali

AU - Wade-Oliver, Kurombi

AU - Karrison, Theodore

AU - Mani, Sridhar

AU - Vokes, Everett E.

PY - 2004/8

Y1 - 2004/8

N2 - 9-Aminocamptothecin (9-AC) is a water-insoluble camptothecin derivative that demonstrated broad activity in pre-clinical studies. In vitro, greater anti-tumor efficacy can be achieved with prolonged administration. A minor response was observed in gastric cancer in a phase I study. We conducted a phase II study of 9-AC in 15 patients with previously untreated metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction. 9-AC was administered at a dose of 25 μg/m2/h over 120 hours (3000 μg/m2 over 5 days) on two consecutive weeks every 21 days. Fourteen patients were evaluable for response. There were no objective responses. Three patients had stable disease lasting a median of 3.4 months (range 1.6-4.3 months). Median time to progression was 1.4 months; median survival was 5.2 months. Grade 3 neutropenia developed in 20% of patients, and anemia in 7%. Grade 3 nausea and fatigue each developed in 7% of patients. We conclude that 9-AC given by 120-hour continuous infusion demonstrates no clinical activity in patients with metastatic gastric cancer.

AB - 9-Aminocamptothecin (9-AC) is a water-insoluble camptothecin derivative that demonstrated broad activity in pre-clinical studies. In vitro, greater anti-tumor efficacy can be achieved with prolonged administration. A minor response was observed in gastric cancer in a phase I study. We conducted a phase II study of 9-AC in 15 patients with previously untreated metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction. 9-AC was administered at a dose of 25 μg/m2/h over 120 hours (3000 μg/m2 over 5 days) on two consecutive weeks every 21 days. Fourteen patients were evaluable for response. There were no objective responses. Three patients had stable disease lasting a median of 3.4 months (range 1.6-4.3 months). Median time to progression was 1.4 months; median survival was 5.2 months. Grade 3 neutropenia developed in 20% of patients, and anemia in 7%. Grade 3 nausea and fatigue each developed in 7% of patients. We conclude that 9-AC given by 120-hour continuous infusion demonstrates no clinical activity in patients with metastatic gastric cancer.

KW - 9-aminocamptothecin

KW - Clinical trial

KW - Gastric cancer

KW - Gastroesophageal junction

UR - http://www.scopus.com/inward/record.url?scp=3543011973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543011973&partnerID=8YFLogxK

U2 - 10.1023/B:DRUG.0000026259.28395.c2

DO - 10.1023/B:DRUG.0000026259.28395.c2

M3 - Article

VL - 22

SP - 323

EP - 327

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -